Closing the Global Health Gap: Progress Against HIV, TB, and Malaria

By HEOR Staff Writer

August 1, 2023

In the last two decades, the world has seen significant strides in global health, particularly in combating HIV, TB, and malaria. This Oxford study shows that these efforts have not only saved lives but also reduced health inequality and inequity, especially in countries furthest behind.

The article discusses the use of summary indicators of health inequality and inequity to assess improvements in global health outcomes, focusing on HIV, TB, and malaria in fifteen countries in sub-Saharan Africa. The study aims to provide a new perspective on how well health gains benefit countries that are furthest behind in terms of health and economic capacities by using the Gini index and a concentration index ranking countries by gross domestic product (GDP) per capita as indicators of health inequality and inequity.

It was found that from 2002 to 2019, there were significant gains in life expectancy in countries with the lowest life expectancy or low economic development. Inequality in life expectancy across countries declined by one-third during this period, with reduced mortality from HIV, TB, and malaria accounting for half of this gain. The article highlights the importance of considering indicators of health inequality in global health, as it provides valuable insights into health gains.

Reference url

Recent Posts

National HealthTech Access: Transforming NHS Adoption and Equity

By João L. Carapinha

February 9, 2026

HealthTech NHS Access Revolutionized by National Programme HealthTech NHS Access is set to transform through the National HealthTech Access Programme (NHAP), announced by
Healthcare Innovation Trends Shaping the Future: Insights from the J.P. Morgan Conference

By HEOR Staff Writer

February 6, 2026

Healthcare Innovation Trends Spotlighted at J.P. Morgan Conference Healthcare innovation trends took center stage at the J.P. Morgan Healthcare Conference, the industry's largest global event, where investors, leaders...
Ozempic Public Funding Approval in Portugal: Key Insights and Implications

By HEOR Staff Writer

February 3, 2026

Ozempic public funding is now approved in Portugal for specific adults with type 2 diabetes. Infarmed's recent decision reimburses semaglutide (Ozempic) through the National Health Service (SNS). It targets those with inadequately controlled type 2 diabetes, BMI ≥30 kg/m², or high cardiovascular ...